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Implementation of a Pharmacy-Based Adult Vaccine Benefit: 
Recommendations for a Commercial Health Plan Benefit
Kelly J. Ko, PhD; Rolin L. Wade, RPh, MS; Hsing-Ting Yu, MPH; Ross M. Miller, MD, MPH; 
Bruce Sherman, MD; and Jeff Goad, PharmD, MPH
ABSTRACT
BACKGROUND: Although vaccination rates in children exceed 90% in the 
United States, adults are vaccinated at far lower rates. In order to address 
this issue, additional community immunizers are needed, and pharmacists 
are in an ideal position to fill this void. 
OBJECTIVES: To explore issues and barriers related to implementation of a 
pharmacy-based adult vaccine benefit and develop recommendations sup-
porting a pathway for benefit expansion. 
METHODS: A literature review on the current environment surrounding 
pharmacy-based adult vaccinations and structured interviews were con-
ducted to inform an expert panel meeting using a modified Delphi process 
(pre/post survey). The goal was to develop recommendations on how to 
improve access to adult vaccines. 
RESULTS: Findings suggest employers play a key role in requesting chang-
es in benefit design to include pharmacy-based vaccinations. However, the 
lack of consistent communication between pharmacists and primary care 
providers remains a significant barrier.
CONCLUSIONS: Pharmacy-based access to vaccinations improves patient 
access and benefits individuals and employers. In order to take advantage 
of this opportunity, pharmacists must be viewed within the broader context 
of preventative care, including pharmacy-based vaccinations.
J Manag Care Pharm. 2014;20(3):273-82




•	To	 address	 this	 issue,	 additional	 community	 immunizers	 are	
needed,	and	pharmacists	are	in	an	ideal	position	to	fill	this	void.	
•	A	 pharmacy-based	 benefit	 would	 improve	 patient	 access	 and	
reduce	the	incidence	of	vaccine-preventable	disease.	
What is already known about this subject
•	Exploration	of	issues	and	barriers	related	to	implementation	of	a	
pharmacy-based	adult	vaccine	benefit.	
•	Specific	 recommendations	 supporting	 a	 pathway	 for	 health	
benefit	 expansion	 from	a	health	plan,	employer,	 and	pharmacy	
perspective.
What this study adds
The	rate	of	adult	immunization	is	suboptimal	in	the	United	States.	 In	 contrast	 with	 childhood	 vaccination	 rates,	adult	vaccination	rates	remain	low	for	most	Centers	for	
Disease	 Control	 and	 Prevention	 (CDC)	 Advisory	 Committee	












ies	 to	 improving	adult	vaccination	rates	 include	failure	of	 the	
vaccine	 delivery	 system	 to	 reach	 target	 populations,4,5 lack 
of	 public	 knowledge	 regarding	 risks	 of	 vaccine-preventable	
diseases,6,7	 skepticism	 regarding	 vaccine	 safety	 and	 effective-
ness,6-8	 lack	 of	 financial/reimbursement	 systems	 for	 provid-








community	 immunizers	 who	 can	 supplement	 the	 role	 of	
primary	 care	 providers	 (PCPs)	 becomes	 pertinent	 given	 that	
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1	was	 invited	to	participate	 in	 the	expert	panel	meeting.	The	
structured	 interview	 guide	 was	 used	 to	 address	 9	 open-
ended	questions	(see	Appendix	A,	available	 in	online	article).	
Participation	 in	 the	 structured	 interview	 was	 voluntary,	 and	










on	 their	 organizational	 (i.e.,	 health	 plan,	 large	 employers)	 or	
















disagreement	 among	 the	 various	 stakeholders.	 By	 doing	 so,	
the	 subsequent	 in-person	 discussion	 could	 be	more	 focused.	
In	 round	2,	at	 the	close	of	 the	meeting,	panelists	were	asked	
to	complete	a	postmeeting	survey	consisting	of	select	opinion-
based	 questions	 from	 the	 premeeting	 survey	 to	 determine	











relevant	 to	 a	 pharmacy-based	 benefit.	 The	 survey	 asked	 
However,	 while	 the	 community	 pharmacy	 is	 in	 an	 excellent	
position	 to	 support	 national	 adult	 immunization	 goals,	 there	
are	a	 limited	number	of	commercial	health	plans	 that	offer	a	
pharmacy-based	 immunization	 benefit,	 and	 even	 when	 pro-
vided,	not	 all	ACIP-recommended	adult	 vaccines	 are	 covered	
or	available	at	the	pharmacy.	The	objectives	of	this	study	were	
to	 explore	 issues	 and	barriers	 related	 to	 implementation	of	 a	
pharmacy-based	 adult	 vaccine	 benefit	 and	 develop	 specific	




rounding	 pharmacy-based	 adult	 vaccinations	 and	 structured	
interviews	 with	 professionals	 highly	 knowledgeable	 about	





pharmacy-based	 adult	 vaccine	 benefit.	 This	 led	 to	 a	 full-day	
expert	 panel	 meeting	 composed	 of	 individuals	 with	 experi-
ence	and	expertise	in	pharmacy-based	adult	vaccinations,	with	
the	goal	of	developing	specific	recommendations	and	building	
consensus	where	 possible	 for	 improving	 access	 to	 adult	 vac-
cines	 through	 a	 pharmacy-based	 immunization	 benefit.	 This	




A	 comprehensive	 literature	 review	 was	 conducted	 to	 iden-
tify	 relevant	 papers	 in	 the	 peer-review	 literature	 (MEDLINE	
2002-January	 2013).	 In	 addition,	 a	 search	 of	 nonindexed	
sources	 including	 professional	 association	 websites	 such	 as	
America’s	Health	Insurance	Plans,	Academy	of	Managed	Care	










Following	 the	 literature	 review,	 a	 series	 of	 brief	 (20-30	min-
utes)	 structured	 telephone	 interviews	were	 conducted	with	 a	
convenience	sample	of	3	opinion	leaders	knowledgeable	about	
pharmacy-based	 immunization	 benefits.	 Participants	 for	 the	
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panelists	 to	 provide	 ratings	 on	 a	 9-point	 scale	 (1	=	strongly	
disagree;	5	=	uncertain;	9	=	strongly	 agree),	 as	well	 as	 respond	
to	 several	 open-ended	 questions.	 Average	 ratings	 between	 1	
and	 3	 were	 considered	 as	 indicating	 disagreement,	 average	




rated	 the	same	statement	as	agree	 (7-9),	 regardless	of	average	
rating.	The	survey	included	3	separate	sections	focusing	on	(a)	
background	knowledge	on	adult	vaccinations,	(b)	perspective	








open	 discussion	 about	 the	 current	 state	 of	 pharmacy-based	
adult	vaccine	benefits.	Panelists	were	provided	with	an	over-
view	of	findings	from	the	literature	review	and	encouraged	to	






rate	on	 their	 responses	 (see	Appendix	C,	 available	 in	online	
article).	 The	 goal	 for	 the	 second	 session	was	 to	 reach	 initial	
consensus	on	issues	where	survey	results	indicated	there	was	
disagreement.	The	goal	of	the	third	session	was	to	share	new	
information	 and	 research	 regarding	 pharmacists	 as	 vaccina-
tors	and	 issues	 related	 to	vaccine	 financing	currently	and	 in	




that	were	 previously	 identified	 through	 the	 literature	 review	
and	structured	interviews.	The	goal	of	the	fourth	session	was	





The	 response	 rate	 for	 the	 pre-	 and	 postmeeting	 survey	 was	
100%	(n	=	12),	 and	 there	were	no	missing	data.	Select	 results	
from	both	 the	 pre-	 and	postmeeting	 survey	 are	 presented	 in	
Table	1.	The	premeeting	survey	asked	panelists	to	rate	various	








Prea Posta Pre Post Pre Post Pre Post
Health	plan	benefit	design	impacts	adult	vaccination	rates 1 2 2 2 9 8 7.08 6.58
Lack	of	public	recognition	regarding	need	for	adult	vaccinations	impacts	adult	
vaccination	rates
1 0 2 1 9 11 7.25 7.83
Cost	of	vaccines	for	patients	impacts	adult	vaccination	rates 2 3 6 5 3 4 5.75 5.25
Vaccine	shortages	impact	adult	vaccination	rates 4 4 2 4 6 4 5.33 5.42
Physicians	are	responsible	for	helping	to	improve	adult	vaccination	rates 0 0 0 0 12 12 8.33 8.58
Patients	are	responsible	for	helping	to	improve	adult	vaccination	rates 0 1 1 0 11 11 7.92 7.67
Health	plans	are	responsible	for	helping	to	improve	adult	vaccination	rates 1 0 0 3 11 9 7.50 7.42
A	pharmacy-based	adult	vaccination	benefit	would	improve	adult	 
vaccination	rates
1 0 0 1 11 11 7.17 7.50
A	pharmacy-based	adult	vaccination	benefit	would	result	in	cost	savings	for	the	
health	plan	and	employer
1 2 4 4 7 6 6.75 5.83
A	pharmacy-based	benefit	would	improve	public	acceptance	of	vaccine	 
safety/effectiveness
1 1 5 3 6 8 6.00 6.50
Ease	of	access	for	patients	is	important	when/if	considering	a	pharmacy-based	
adult	vaccine	benefit
1 1 1 1 10 10 7.42 7.75
Coordinated	reporting	of	vaccines	is	important	when/if	considering	a	
pharmacy-based	adult	vaccine	benefit
0 0 3 0 9 12 7.25 8.33
Lack	of	standard	reimbursement	process	is	a	significant	barrier 2 0 1 2 9 10 6.92 7.75
Uncertain	cost-effectiveness	is	a	significant	barrier 4 1 5 7 3 4 5.08 5.67
Safety	of	vaccines	administered	by	pharmacists	is	an	issue 5 7 4 4 3 1 4.75 3.25
aDenotes number of panelists who were in disagreement, unsure, or agreement with respective survey questions.
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design	and	lack	of	public	recognition	regarding	the	importance	
of	 adult	 vaccinations	 were	 important	 barriers	 to	 improving	
adult	 vaccination	 rates.	 However,	 panelists	 disagreed	 on	 the	
importance	of	 the	cost	of	vaccines	and	 the	 impact	of	vaccine	
shortages	 on	 adult	 vaccination	 rates.	 When	 panelists	 were	
asked	 what	 they	 believed	 were	 the	 most	 significant	 barriers	
to	improving	adult	vaccination	rates,	payment	processing	and	
lack	of	coordinated	reporting	were	most	frequently	identified.	
When	 asked	 about	 who	 was	 most	 responsible	 for	 improv-
ing	 vaccination	 rates,	 they	 reported	physicians,	 patients,	 and	
health	 plans,	 while	 there	 was	 disagreement	 regarding	 the	
responsibility	of	government	 regulators	and	government	pay-
ers	 on	 improving	 rates.	 Although	 panelists	 were	 in	 general	
agreement	 that	 pharmacy-based	 vaccination	 could	 improve	
vaccination	 rates	 and	 result	 in	 cost	 savings,	 there	 was	 only	
moderate	agreement	that	a	pharmacy-based	benefit	would	help	
improve	public	acceptance	of	vaccine	safety	and	effectiveness.	
For	 those	 considering	 a	 pharmacy	 benefit,	 ease	 of	 access	 for	
patients	 and	 coordinated	 reporting	 of	 vaccine	 administration	
were	most	important.	However,	there	was	a	lack	of	consensus	
when	 it	 came	 to	 the	 safety	 of	 vaccinations	 administered	 by	
pharmacists,	due	to	the	lack	of	pharmacists	having	access	to	a	
full	patient	history.	When	asked	about	the	most	useful	type	of	
information	 in	 evaluating	 a	 pharmacy-based	 vaccine	 benefit,	
models	 of	 best	 practice	 and	 vaccine	 registries	 were	 reported	
as	 most	 useful.	 Panelists	 disagreed	 regarding	 the	 utility	 of	
cost-effectiveness	 modeling,	 retrospective	 claims	 research,	





of	 pharmacy-based	benefits	 (see	Table	1).	 For	 instance,	 post-
meeting	 results	 indicated	 that	 panelists	 still	 disagreed	 about	
which	 factors	would	 impact	 adult	 vaccination	 rates	 (i.e.,	 vac-
cine	cost	and	vaccine	shortages)	and	who	was	most	responsible	




whether	 standardization	 of	 the	 payment	 process,	 uncertain	
cost-effectiveness,	and	safety	concerns	over	pharmacists	as	vac-
cinators	were	barriers	to	a	pharmacy-based	benefit.	According	
to	 postmeeting	 results,	 panelists	 agreed	 that	 uncertain	 cost-
effectiveness	and	 the	 lack	of	a	 standardized	payment	process	
were	 barriers	 to	 a	 pharmacy-based	 benefit,	 but	 not	 safety	 of	
pharmacist-administered	 vaccinations.	 Other	 areas	 where	
consensus	was	achieved	include	the	utility	of	cost-effectiveness	
modeling,	 retrospective	 claims	 analysis,	 and	 patient	 surveys,	
but	all	of	these	were	considered	only	moderately	useful.	
Overall,	results	from	the	literature	review,	structured	inter-
views,	 and	 premeeting	 survey	 identified	 6	 broad	 areas	 that	
provided	direction	for	the	expert	panel	meeting:	benefit	design,	









Benefit Design.	 Panelists	 agreed	 that	 one	 of	 the	 most	 sig-
nificant	barriers	to	improving	adult	vaccination	rates	is	benefit	
design	 in	 that	members	 are	 simply	not	 aware	of	 the	benefits	





offering	 free	 vaccines	 is	 an	 insufficient	 incentive	 to	 increase	
vaccination	 rates	 and	 that	 members	 may	 need	 additional	
incentives	(e.g.,	discounts	on	premiums)	in	addition	to	provid-





From	 an	 administrative	 standpoint,	 panelists	 reported	
that	benefit	design	 is	strongly	affected	by	 third-party	brokers	
of	 medical	 and	 pharmacy	 benefits.	 Brokers	 often	 purchase	







to	 keep	 brokers	 accountable	 in	 offering	 data	 integration	 and	
for	buyers	to	include	these	services	in	the	purchasing	decision.	
The	 panelists	 representing	 employers	 conveyed	 that	 out-
side	 of	 influenza,	 they	were	 unaware	 of	 data	 suggesting	 any	
worker	 productivity	 benefits	 of	 increasing	 the	 rate	 of	 adult	
vaccinations	or	 expanding	 such	 a	benefit.	These	payers	were	
not	convinced	of	the	cost-benefit	of	additional	adult	vaccines,	
particularly	 when	 balancing	 the	 additional	 cost	 of	 increased	
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administration	of	 those	benefits	by	 the	PBM	and	health	plan	
are	 a	 significant	 barrier.	 Moreover,	 payment	 processes	 were	
also	seen	as	one	of	the	most	important	factors	when	consider-




health	 plan	 had	 already	 reimbursed	 a	 pharmacy	 for	 admin-




Options	 for	 pharmacy	 billing	 of	 vaccination	 were	 also	
discussed,	 and	 the	 consensus	 opinion	 was	 that	 it	 would	 be	
most	 efficient	 to	 have	 pharmacies	 use	 the	 current	 National	




on	 the	 medical	 claim	 process.	 Rather	 than	 compel	 pharma-
cies	to	submit	claims	using	the	medical	benefit	billing	system,	
the	 panel	 agreed	 that	 health	 plans	 and	 PBMs	 should	 accept	
billing	 for	 pharmacy	 administration	 of	 vaccines	 through	 the	




Regulatory/Scope of Practice.	 Although	 pharmacists	 are	
authorized	 to	 administer	 vaccines	 in	 every	 state,	 variations	
exist	regarding	the	type	of	vaccines	and	age	of	eligible	patients	
to	which	pharmacists	can	administer	vaccines.	Large	employ-
ers	with	 a	 presence	 in	multiple	 states	 specifically	mentioned	





Among	 those	 who	 agreed	 state	 laws	 were	 a	 barrier	 to	 a	
pharmacy	 benefit,	 panelists	 mentioned	 that	 state	 medical	
association	 support	would	 likely	be	 required	 to	 expand	 state	
practice	 laws.	 In	 particular,	 state	 medical	 associations	 with	
the	 assistance	 of	 state/county	 public	 health	 associations	 and	
physician	groups	could	help	to	support	expanded	state	regula-
tions	 authorizing	 pharmacists	 as	 full	 vaccine	 providers.	 The	
Patient	Centered	Primary	Care	Collaborative	was	suggested	as	
a	national	 organization	 that	 could	 fashion	 a	policy	 statement	
to	be	utilized	 at	 the	 state	 level	 to	 support	 expanded	practice	
authority	for	pharmacist	vaccine	administration.
Physician	 panelists	 reported	 that	 physicians	 are	 generally	
comfortable	with	 pharmacists	 as	 vaccine	 providers,	 although	
the	 ability	 of	 pharmacists	 to	 properly	 screen	 patients	 for	 a	
wide	 range	 of	 vaccinations	 with	 limited	 patient	 history	 did	
raise	 some	 concern.	 Recent	 efforts	with	 the	H1N1	pandemic	
program	 were	 cited	 as	 a	 model	 of	 how	 loosening	 state	 law	
during	 a	 pandemic	 for	 pharmacists	 can	 be	 very	 effective	 at	
rapidly	increasing	vaccination	rates.	For	example,	pharmacist-
provided	 immunizations	 expanded	 considerably	 following	
the	 2009	 H1N1	 influenza	 pandemic	 and	 seasonal	 influenza	
outbreak.	 This	 public	 health	 crisis	 highlighted	 the	 role	 that	
pharmacists	can	play	and	positioned	the	profession	to	continue	
advancing	 immunization	 opportunities	 that	 improve	 public	
health	by	reaching	patient	populations	in	need	or	at	risk.15,16 











for	 pharmacists.	 Provider	 status	 for	 pharmacists	 under	 the	
Social	Security	Act	is	generally	thought	to	be	necessary	to	allow	
pharmacists	 to	 be	 consistently	 paid	 by	Medicaid	 and	private	
insurers.	When	asked	to	elaborate,	those	expressing	hesitancy	
over	pharmacists	 as	vaccine	providers	 indicated	 that	without	
appropriate	 information	 exchange	 (i.e.,	 communication	 back	
to	 the	 PCP),	 physicians	 remain	 reluctant	 to	 recognize	 other	
providers	as	vaccinators.	It	appears	that	consensus	is	unlikely	
to	be	achieved	regarding	the	recognition	of	pharmacists	as	vac-
cine	providers	until	 information	 exchange	 is	more	 effectively	
coordinated	between	pharmacists	and	PCPs.	It	is	important	to	







Immunization Documentation and Communication.	 There	
was	 broad	 agreement	 that	 lack	 of	 coordinated	 care	 between	
pharmacies	 and	 PCPs	 was	 a	 significant	 barrier	 related	 to	
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play	 a	 more	 substantial	 role	 in	 increasing	 adult	 vaccination	
rates.	 Health	 plan	 representatives	 reported	 that	 one	 of	 their	
primary	concerns	was	whether	or	not	community	pharmacies	
could	provide	consistent	services	across	locations	and	be	able	
to	 deliver	 vaccinations	 during	 all	 business	 hours.	 However,	
professional	 pharmacy	 associations	 report	 that	 pharmacists	







administration,	 the	 expectation	was	 that	 pharmacists	 should	
leverage	patient	 encounters	 to	not	only	provide	vaccines,	but	
also	 take	 the	 opportunity	 to	 provide	 other	 preventive	 health	










were	also	addressed	by	 the	panel.	The	panel	 recognized	 that	
health	plans	and	PBMs	often	operate	independently	and	under	
different	medical	 and	pharmacy	benefit	 silos.	Regardless,	 the	
panel	 believed	 these	 entities	 were	 responsible	 for	 and	 best	
positioned	 to	 provide	 data	 integration	 across	 providers.	 In	
addition,	health	plans	and	PBMs	should	work	with	employers	
to	 improve	 the	 patient	 experience	 accessing	 and	 using	 their	
health	benefits.	While	vaccine	manufacturers	were	seen	as	just	
moderately	 responsible	 for	 improving	adult	vaccination	rates,	
the	panel	 strongly	 suggested	 that	manufactures	were	 respon-
sible	for	the	perception	of	vaccine	efficacy,	safety,	and	value	by	
providing	appropriate	messaging	with	high-quality	evidence.	
Consensus	was	not	achieved	 regarding	 the	 role	of	govern-
ment	 regulators	 and	 government	 payers	 (e.g.,	 Centers	 for	
Medicare	 &	 Medicaid	 Services)	 and	 their	 responsibility	 in	
improving	 adult	 vaccination	 rates.	Among	 those	who	 felt	 the	








series,	 such	 as	 that	 for	HPV	 or	 hepatitis	 B.	 It	was	 suggested	
that	the	PCP	could	administer	the	first	vaccination,	with	sub-




the	 pharmacy/pharmacist,	 the	 issue	 of	 information	 exchange	
could	 also	 be	 addressed	 while	 also	 utilizing	 the	 increased	
accessibility	of	community	pharmacists.
Panelists	 also	 suggested	 the	 inclusion	 of	 pharmacists	 in	
other	 electronic	 reporting	 solutions,	 such	 as	 immunization	
registries	 or	 state	 health	 information	 exchanges,	 as	 a	way	 to	
increase	coordinated	care	between	pharmacists	and	PCPs.	For	
example,	 providing	 pharmacists	 access	 to	 highly	 populated	
registries	 would	 allow	 pharmacists	 to	 actively	 seek,	 contrib-
ute,	 and	view	 immunization	 records	 so	 that	 all	providers	are	




cian’s	medical	 record	using	only	 their	 pharmacy	 information	
management	system.	Lastly,	panelists	reported	that	the	expec-
tation	 under	 new	 state	 health	 information	 exchanges	 (HIEs)	
is	 that	 every	 provider	will	 have	 access	 to	 a	 real-time	 patient	
record,	which	 could	be	used	 as	 a	 central	 vaccination	 record.	
However,	in	order	for	this	to	work,	there	is	a	need	to	have	phar-
macists	recognized	as	providers	within	the	HIEs.	Establishing	
pharmacists	 as	 providers	 through	 state	 HIEs,	 coupled	 with	
access	to	patient	records,	may	provide	a	reporting	mechanism	
to	PCPs	and	a	basis	for	pharmacists	to	administer	all	vaccines.	
As	 with	 any	 reporting	 system,	 it	 is	 essential	 that	 providers	
check	 the	 system	 prior	 to	 providing	 services,	 something	 the	
panel	 indicated	 that	 neither	 physicians	 nor	 pharmacists	 cur-
rently	do	well,	since	they	are	better	at	data	entry	than	retrieval.
Responsibility for Vaccination Rates.	 Panelists	 identified	
physicians	 as	 the	 most	 responsible	 for	 the	 improvement	 in	
adult	 vaccination	 rates,	 followed	by	patients,	 insurance	 com-
panies,	 pharmacists,	 and	 employers.	 In	 addition,	 panelists	
focused	on	employers	as	having	the	potential	to	play	a	pivotal	
role	 in	 the	 improvement	 of	 adult	 vaccination	 rates.	 It	 was	
suggested	 that	 employers	 can	 specifically	 request	 that	 their	
health	plans	 and	brokers	 include	 a	pharmacy-based	 vaccina-
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■■  Discussion
The	 Patient	 Protection	 and	 Affordable	 Care	 Act	 (PPACA),	
signed	into	law	in	2010,	requires	government	and	commercial	
plans	 to	 cover	 essential	benefits,	which	 include	wellness	 and	
clinical	preventive	services,	 including	vaccines	recommended	




Pharmacists	 and	 community	 pharmacy	 locations	 are	 in	
an	 ideal	 position	 to	meet	 this	 growing	 need	 for	 preventative	
services.	 Pharmacist-provided	 immunizations	 are	 clinically	
sound,	cost	effective,	readily	accessible,	and	have	demonstrated	
the	ability	to	support	our	nation’s	public	health	goals.	Although	
there	 are	 varying	 state	 regulations	 regarding	 pharmacists	 as	
vaccine	 administrators,	 all	 50	 states	 currently	 allow	pharma-
cists	to	administer	vaccines.17,21,22	Duncan	et	al.	(2012)	created	
a	 cost-benefit	 model	 around	 influenza	 vaccination	 programs	
and	reported	that	an	influenza	immunization	program	is	cost	




of	 vaccination	was	 lower	 in	mass	 vaccination	 clinics	 ($17.04)	
and	 pharmacy	 ($11.57)	 settings	 than	 in	 scheduled	 doctor’s	
office	visits	($28.67).24
The	purpose	of	this	project	was	to	identify	issues	and	bar-
riers	 related	 to	 a	 pharmacy-based	 adult	 vaccine	 benefit	 and	
develop	 recommendations	 to	 support	 a	 pathway	 for	 benefit	
design	change.	Based	on	our	findings,	the	barriers	associated	
with	 overcoming	 a	 pharmacy-based	 benefit	 revolve	 around	
3	 distinct	 areas:	 increased	 engagement	 by	 employers,	 lack	 of	
coordinated	reporting,	and	insufficient	recognition	of	the	com-
munity	pharmacy	and	pharmacist	as	vaccine	providers.	
First,	 it	 is	 clear	 that	 employers	 must	 play	 a	 more	 proac-
tive	 role	 in	 incorporating	 explicit	 changes	 in	 benefit	 design.	
However,	 in	 order	 to	 consider	 any	 benefit	 changes,	 they	
require	 sound	 value	 propositions	 to	 guide	 directed	 use	 of	
limited	organizational	resources.	As	such,	pharmacy	vaccina-
tion	 benefit	 would	 have	 to	 show	 relatively	 greater	 near-term	
value	in	comparison	to	other	health	management	initiatives	to	
prompt	 sufficient	 employer	 focus	 to	 enhance	 vaccine	 benefit	
design.	Although	employers	are	not	necessarily	calling	for	cost-
effectiveness	data	given	the	relatively	low	cost	of	vaccines,	they	
would	benefit	 from	more	 substantial	 evidence	demonstrating	
the	impact	of	adult	vaccines	on	health	care	costs	and	workforce	
productivity	and	absenteeism.	
Second,	 from	 an	 administrative	 standpoint,	 the	 ability	 to	
ensure	consistent	reporting	and	data	exchange	between	com-
munity	 pharmacists	 and	 PCPs	 is	 of	 significant	 importance.	
Due	 to	 issues	 such	 as	 the	 potential	 for	 duplicative	 billing	
and	 lack	 of	 data	 exchange	 between	 pharmacies	 and	 PCPs,	
government	had	a	 limited	 role,	 it	was	 suggested	 that	govern-
ment	 responsibilities	 for	 adult	 vaccinations	 were	 limited	 to	
public	health	agency	recommendations.	
Future Research.	 Employers	 called	 for	 additional	 research	
demonstrating	the	value	of	adult	vaccines	beyond	seasonal	flu.	
It	was	 apparent	 that	 employers	 remained	 skeptical	 regarding	
the	 near-term	 value	 associated	 with	 increasing	 adult	 vacci-
nation	 rates	 by	 offering	 adult	 vaccines	 through	 pharmacy-
delivered	benefits	or	other	providers.	Employers	are	interested	
in	additional	information	to	help	them	determine	the	value	of	
increasing	 adult	 vaccination	 rates	 and	offering	 the	 additional	
benefit	of	pharmacy-based	vaccinations.	





the	 various	 adult	 vaccines,	 as	 panelists	 generally	 agreed	 that	
















expanded	 access.	 Focusing	 on	 adult	 vaccinations	 as	 part	 of	
quality	 measures	 would	 help	 all	 stakeholders	 recognize	 the	
importance	of	adult	vaccines.	
Panelists	 identified	 that	 the	 2	 most	 important	 sources	 of	
information	when	evaluating	the	impact	of	a	pharmacy-based	
benefit	were	peer-review	journals	and	ACIP	recommendations.	





were	 asked	 to	 provide	 specific	 actionable	 recommendations	
across	 the	 6	 topics	 discussed	 throughout	 the	 expert	 panel	
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competition	 for	 patients,	 and	 potential	 revenue	 loss,	 there	 is	
reluctance	 among	 physicians	 and	 health	 plans	 to	 recognize	
pharmacists	as	vaccine	providers.	However,	this	does	not	call	
for	an	entirely	new	billing	system;	instead,	the	preference	is	to	












opportunity	 and	 obligation	 to	 serve	 a	 broader	 role.	 If	 phar-
macists	 are	 to	 be	 recognized	 as	 providers,	 they	 must	 take	
advantage	of	the	patient	encounter	and	provide	other	preven-











Lastly,	 despite	 PPACA	 legislation	 and	 first-dollar	 coverage	
for	 adult	 vaccinations,	 utilization	 rates	 remain	 low.25	 There	
is	 a	 compelling	need	 for	 enhanced	 awareness	 of	 the	 value	of	
adult	vaccinations.	All	stakeholders	in	the	health	care	delivery	
system	can	advocate	for	improved	immunization	rates	by	pro-
moting	 available	 vaccination	 sources,	 including	 pharmacies.	
Additionally,	 employers	 can	 enhance	 communication	 efforts	














































ACIP = Advisory Committee on Immunization Practice; EMR = electronic medical record; HEDIS =Healthcare Effectiveness Data and Information Set; HIE = health  
information exchange; PBM = pharmacy benefit manager.
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One	 pharmacy	 director	 from	 a	 national	 health	 plan	 chose	 to	 remain	
anonymous.
We	 also	 gratefully	 acknowledge	 the	 very	 important	 contributions	 of	






















There	 are	 several	 limitations	 to	 be	 noted.	 First,	 due	 to	 the	
scope	of	 the	project,	a	convenience	sample	of	12	participants	
were	 included	 in	 the	 expert	 panel,	 and	 workgroup	 recom-
mendations	may	not	 be	 representative	 of	 other	 organizations	
or	states.	For	example,	we	only	included	employer	representa-





relevant	 topics	 to	 a	 pharmacy-based	benefit.	 As	 a	 result,	 our	
study	focused	on	6	broad	topics,	but	other	factors	are	likely	to	
be	important	when	considering	the	merits	of	pharmacy-based	
vaccination.	 Panelists	 clearly	 indicated	 vaccines	were	 viewed	















of	 preventative	 health	 care,	 which	 includes	 pharmacy-based	
adult	vaccinations.
DISCLOSUReS














The	authors	would	 like	 to	 thank	 the	panelists	 for	 their	participation	 in	 the	
expert	panel	meeting:
KELLY J. KO, PhD, is Research Scientist; HSING-TING YU, 
MPH, is Principle Investigator; and ROSS M. MILLER, MD, 
MPH, is Medical Executive, Cerner Corporation, Culver City, 
California. ROLIN L. WADE, RPh, MS, is a Principle, IMS Health, 
Parsippany, New Jersey; BRUCE SHERMAN, MD, is Medical 
Director, Employers Health Coalition, Inc., Canton, Ohio, and 
Assistant Clinical Professor, Case Western Reserve University School 
of Medicine, Cleveland, Ohio; and JEFF GOAD, PharmD, MPH, 
is Associate Professor, University of Southern California School of 
Pharmacy, Los Angeles, California.
AUTHOR CORRESPONDENCE: Kelly J. Ko, PhD, Cerner 
Research, 600 Corporate Pointe, Ste. 320, Culver City, CA 90230. 












































282 Journal of Managed Care & Specialty Pharmacy JMCP March 2014 Vol. 20, No. 3 www.amcp.org























Pharmacists	and	immunizations:	a	national	survey. J Am Pharm Assoc (Wash). 
2001;41(1):32-45.
23.	Duncan	IG,	Taitel	MS,	Zhang	J,	Kirkham	HS.	Planning	influenza	vacci-
















telephone	survey	of	persons	with	cardiovascular	disease.	Tex Heart Inst J. 
2009;36(6):546-52.
9.	Committee	on	the	Evaluation	of	Vaccine	Purchase	Financing	in	the	
































282a Journal of Managed Care & Specialty Pharmacy JMCP March 2014 Vol. 20, No. 3 www.amcp.org
Implementation of a Pharmacy-Based Adult Vaccine Benefit: Recommendations for a Commercial Health Plan Benefit
Adult Immunization Background
1. Tell me about your adult vaccine benefit [HeALTH PLAn ReSPOnDenTS]
	 a.	 What	adult	vaccines	are	covered	and	under	what	type	of	benefit?	Any	restrictions	on	particular	adult	vaccines?	
	 	 i.	 Flu,	pneumovax,	H	Zoster,	Td,	Tdap,	Hep	A,	Hep	B,	MMR,	meningitis,	others
	 b.	 Are	your	adult	vaccines	covered	under	a	pharmacy	benefit	or	via	alternate	benefit	arrangements,	or	only	under	a	medical	benefit?
 What adult vaccines are you aware of that are covered by health insurance? [nOn-HeALTH PLAn ReSPOnDenTS]




	 	 i.	 Were	(do	you	believe)	these	improvement	strategies	(are)	successful?	Why	or	why	not?
	 d.	 Are	there	particular	vaccines	that	are	more	difficult	than	others	to	increase	immunization	rates?	(i.e.,	flu,	shingles,	hepatitis)?
	 e.	 How	could	the	benefit	design	affect	(your)	adult	immunization	goals?
Pharmacy-Based Adult Vaccines & Barriers
3. Have you considered (or implemented) a pharmacy-based adult vaccine benefit, or have you discussed this with your health plan?  




	 	 i.	 Are	there	ongoing	challenges?
	 	 ii.	 If	your	health	plan	already	offers	a	pharmacy-based	immunization	benefit,	how	effective	has	it	been	in	terms	of	uptake/completion	rates,	 
	 	 	 cost	savings,	etc?	
	 d.	 If	no,	what	would	increase	your	interest	in	(developing)	a	pharmacy-based	vaccination	benefit?
	 	 i.	 What	do	you	believe	has	to	take	place	in	order	to	provide	pharmacy-based	immunization	benefits?	(In	your	plan	or	health	plans	in	general)
4. What do you believe are the most significant barriers related to implementing a pharmacy-based adult immunizations benefit?











	 	 i.	 Fragmentation	of	immunization	delivery,	lack	of	reporting	to	the	insurer	and	PCP,	over-vaccination	due	to	different	levels	of	insurance	 
	 	 	 verification	(real-time	vs.	retrospective),	skill	level	of	pharmacist,	capitated	vs.	PPO/FFS,	Restricted	Networks	(under	ACA).




6. How important to you are (were) the following considerations in implementing a pharmacy-based adult immunization benefit? 






	 	 i.	 What	specific	data	would	be	useful?
	 	 ii.	 What	are	the	most	important	measures?	
	 	 iii.	 What	inputs	and	outputs	would	you	want	to	see?
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7. What kind of data/studies would be most useful to your health plan when (if) considering an adult vaccine pharmacy-benefit?  
 [HeALTH PLAn ReSPOnDenTS]
 What kind of data/studies do you believe would be most useful for health plans considering an adult vaccine pharmacy-benefit?  
 [nOn-HeALTH PLAn ReSPOnDenTS]
	 a.	 Who	would	be	the	most	appropriate	organization	to	produce	such	data,	inappropriate?	
	 b.	 What	would	you	consider	to	be	important	or	convincing	results?
	 	 i.	 Specifically,	in	what	areas	would	you	need	to	see	changes?
	 c.	 Are	you	aware	of	any	data	supporting	the	value	of	pharmacy-based	programs?	If	so,	what	was	your	impression	of	that	data?
8. Where do you go for tools and advice regarding a pharmacy-based adult vaccination benefit? 
	 a.	 What	guidelines	or	professional	organizations	do	you	most	refer	to	when	considering	benefit	design	change	in	the	area	of	immunization?
9. Would you want a credentialed network of pharmacists who provide your vaccinations? [HeALTH PLAn ReSPOnDenTS]
	 a.	 If	so,	what	would	you	want	to	know	about	them?	(e.g.,	training,	DEA/DOJ/CMS	background,	license	in	good	standing,	etc.)	
APPEnDix A Structured Interview Guide (continued)
ACA = Affordable Care Act; CMS = Centers for Medicare & Medicaid Services; DEA = Drug Enforcement Administration; DOJ = Department of Justice; FFS = fee-for-service; 
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Section I: Background
1. How strongly do you agree or disagree that the following factors impact adult vaccination rates?








2. How much responsibility do the following stakeholders have in helping to improve adult vaccination rates?













3. What do you believe is the most significant barrier/challenge to improving adult vaccination rates?
Section II: Pharmacy-based adult vaccination benefit
4. Does your organization currently offer a pharmacy-based adult vaccine benefit? [HeALTH PLAn PAneLISTS]
 Are you directly involved with any adult-based vaccination programs? [nOn-HeALTH PLAn PAneLISTS]
	 a.	 Yes,	if	so	please	describe	and	for	how	long?
	 b.	 No,	if	not	what	would	increase	your	interest?
5. How strongly do you agree/disagree that pharmacy-based adult vaccination benefit availability would help improve the following:




6. How strongly do you agree/disagree that the following are barriers/challenges related to a pharmacy-based adult vaccine benefit?











7. How important to your decision making are the following factors when considering a pharmacy-based adult vaccine benefit?
 1 = Unimportant, 5 = neutral, 9 = Very important
	 a.	 Ease	of	access	to	vaccinations	for	my	members/employees
	 b.	 Member/employee	satisfaction	or	loyalty	to	the	health	plan/company
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8. What do you believe are the two (2) most significant challenges (to your health plan or to other stakeholders) in establishing a pharmacy-based 
 adult vaccination benefit?
Section III: Future studies/resources
9. What kind of data/study types do you believe are most useful when evaluating a pharmacy-based adult vaccination benefit?









10. What are the most useful/important sources of information when evaluating a pharmacy-based adult vaccine benefit?










11. What public and/or private organizations are best suited or the most credible to conduct studies or disseminate information about  
 pharmacy-based adult vaccination benefits?
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APPEnDix C Supplemental Data
How strongly do you agree or disagree that the following factors impact adult vaccination rates (i.e., uptake/completion)?
Disagreement (1-3) Unsure (5-7) Agreement (7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Health	plan	benefit	design	 1 2 2 2 9 8 7.08 6.58
Scope	of	practice	issues	 1 0 2 2 9 10 7.08 7.42
Lack	of	public	recognition	 1 0 2 1 9 11 7.25 7.83
Public	perception	that	vaccine	risk	>	benefits	 0 1 5 3 7 8 6.75 6.50
Cost	of	vaccines	for	patients	 2 3 6 5 3 4 5.75 5.25
Vaccine	shortages	 4 4 2 4 6 4 5.33 5.42
How much responsibility do the following stakeholders have in helping to improve adult vaccination rates?
Disagreement (1-3) Unsure (5-7) Agreement (7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Patients	 0 1 1 0 11 11 7.92 7.67
Physicians	 0 0 0 0 12 12 8.33 8.58
Pharmacists	 1 0 2 4 9 8 7.00 7.25
Employers	 0 0 4 3 8 9 7.08 7.17
Insurance	companies/health	plans/PBMs 1 0 0 3 11 9 7.50 7.42
Vaccine	manufacturers/suppliers 0 1 4 6 8 5 6.75 5.92
CDC/ACIP 1 1 2 3 9 8 7.17 7.08
Government	regulators 2 3 5 3 5 6 5.50 5.50
Government	payers	(e.g.	CMS) 2 2 0 3 10 7 6.58 6.00
Public	health	agencies	(state,	county) 1 1 1 2 10 7 7.08 6.92
Professional	societies 1 1 5 5 6 6 6.33 6.25
How strongly do you agree/disagree the availability of a pharmacy-based adult vaccination benefit would help improve the following: 
Disagreement (1-3) Unsure (5-7) Agreement (7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Adult	vaccination	rates 1 0 0 1 11 11 7.17 7.50
Cost	savings	for	the	health	plan	and/or	employer 1 2 4 4 7 6 6.75 5.83
Public	acceptance	of	vaccine	safety/effectiveness 1 1 5 3 6 8 6.00 6.50
How strongly do you agree/disagree that the following are barriers/challenges related to a pharmacy-based adult vaccine benefit?
Disagreement (1-3) Unsure (5-7) Agreement (7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Lack	of	standardized	reimbursement	process 2 0 1 2 9 10 6.92 7.75
Coordinated	reporting	of	vaccination	to	PCP 1 2 3 0 8 10 6.75 7.08
Uncertain	cost-effectiveness 4 1 5 7 3 4 5.08 5.67
Increased	net	cost	to	payer	(i.e.,	increase	in	claims) 4 3 7 7 1 2 4.33 5.00
Varying	state	laws	on	pharmacy	regulations 2 2 6 3 4 7 6.08 6.17
Complexity	of	establishing	a	pharmacy	network 2 5 8 5 2 2 5.08 4.33
Recognition	of	the	pharmacist	as	a	vaccine	provider 2 3 6 5 4 4 5.75 5.67
Perception	that	pharmacists	are	taking	revenue 4 3 4 7 4 2 5.08 4.92
Pharmacists	ability	to	safely	administer	vaccines 5 7 4 4 3 1 4.75 3.25
How important to your decision making are the following factors when (if) considering a pharmacy-based adult vaccine benefit?
Disagreement (1-3) Unsure (5-7) Agreement (7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Ease	of	access	to	vaccinations	for	members/employees 1 1 1 1 10 10 7.42 7.75
Member/employee	satisfaction 1 1 4 4 7 7 6.58 6.58
Availability	of	a	wide	range	of	adult	vaccines 1 1 6 7 5 4 6.17 6.00
Reimbursement	processes 1 0 3 0 8 12 6.83 7.67
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What kind of data/study TYPeS do you believe are most useful when evaluating a pharmacy-based adult vaccination benefit?
Disagreement (1-3) Unsure (5-7) Agreement (7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Cost-effectiveness	modeling 4 1 3 0 5 11 5.33 6.58
Prospective	studies 1 0 4 2 7 10 6.42 7.33
Retrospective	administrative	claims	analyses 2 1 4 2 6 9 6.00 6.50
Models	of	best	practice 0 1 5 1 7 10 7.00 7.42
Registry	data 0 0 4 3 8 9 6.83 7.25
Patient	surveys 2 0 6 6 4 6 5.92 6.67
Provider	surveys 1 0 8 4 3 8 5.92 6.08
What are the most useful/important SOURCeS of information when evaluating a pharmacy-based adult vaccine benefit?
Disagreement (1-3) Unsure (5-7) Agreement (7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Morbidity	and	Mortality	Weekly	Report	(MMWR) 2 0 4 4 6 8 6.00 6.92
ACIP	recommendations 0 0 2 3 10 9 7.67 7.50
Peer-reviewed	journal	articles 0 0 5 1 7 11 6.92 7.92
Professional	association	guidelines 0 1 8 3 4 8 5.92 6.58
Professional	conference/meetings 3 1 6 4 3 7 5.25 6.17
Newsletters 4 3 5 6 3 3 4.50 5.00
Discussion	with	colleagues 3 1 6 5 3 6 5.33 6.00
Internet 2 3 8 5 2 4 4.83 5.17
aDenotes number of panelists who were in disagreement, unsure, or agreement with respective survey questions.
ACIP = Advisory Committee on Immunization Practice; CDC = Centers for Disease Control and Prevention; CMS = Centers for Medicare & Medicaid Services;  
PBM = pharmacy benefit manager; PCP = primary care provider.
APPEnDix C Supplemental Data (continued)
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